Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

NCT01855451 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

189

Enrollment

OTHER

Sponsor class

Conditions

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG: Cetuximab
RADIATION: RT (70 Gy in 35 fractions)
DRUG: Cisplatin

Sponsor

Trans Tasman Radiation Oncology Group